| pubmed-article:11496095 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11496095 | lifeskim:mentions | umls-concept:C0031809 | lld:lifeskim |
| pubmed-article:11496095 | lifeskim:mentions | umls-concept:C1533685 | lld:lifeskim |
| pubmed-article:11496095 | lifeskim:mentions | umls-concept:C0024485 | lld:lifeskim |
| pubmed-article:11496095 | lifeskim:mentions | umls-concept:C0450442 | lld:lifeskim |
| pubmed-article:11496095 | lifeskim:mentions | umls-concept:C0754820 | lld:lifeskim |
| pubmed-article:11496095 | lifeskim:mentions | umls-concept:C0675791 | lld:lifeskim |
| pubmed-article:11496095 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:11496095 | pubmed:dateCreated | 2001-8-9 | lld:pubmed |
| pubmed-article:11496095 | pubmed:abstractText | A series of preclinical tests were undertaken during the developmental process to determine the safety profile of gadoversetamide injection (OptiMARK). | lld:pubmed |
| pubmed-article:11496095 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11496095 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11496095 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11496095 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11496095 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11496095 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11496095 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11496095 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:11496095 | pubmed:issn | 0020-9996 | lld:pubmed |
| pubmed-article:11496095 | pubmed:author | pubmed-author:AdamsM DMD | lld:pubmed |
| pubmed-article:11496095 | pubmed:author | pubmed-author:MacDonaldJ... | lld:pubmed |
| pubmed-article:11496095 | pubmed:author | pubmed-author:HynesM RMR | lld:pubmed |
| pubmed-article:11496095 | pubmed:author | pubmed-author:TroupC MCM | lld:pubmed |
| pubmed-article:11496095 | pubmed:author | pubmed-author:BarcoS JSJ | lld:pubmed |
| pubmed-article:11496095 | pubmed:author | pubmed-author:WojdylaJ KJK | lld:pubmed |
| pubmed-article:11496095 | pubmed:author | pubmed-author:GalenK PKP | lld:pubmed |
| pubmed-article:11496095 | pubmed:author | pubmed-author:PeriasamyM... | lld:pubmed |
| pubmed-article:11496095 | pubmed:author | pubmed-author:Wible J HJHJr | lld:pubmed |
| pubmed-article:11496095 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11496095 | pubmed:volume | 36 | lld:pubmed |
| pubmed-article:11496095 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11496095 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11496095 | pubmed:pagination | 401-12 | lld:pubmed |
| pubmed-article:11496095 | pubmed:dateRevised | 2009-11-11 | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:meshHeading | pubmed-meshheading:11496095... | lld:pubmed |
| pubmed-article:11496095 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11496095 | pubmed:articleTitle | Toxicological assessment of gadoversetamide injection (OptiMARK), a new contrast-enhancement agent for use in magnetic resonance imaging. | lld:pubmed |
| pubmed-article:11496095 | pubmed:affiliation | Mallinckrodt Imaging, St. Louis, Missouri 63134, USA. jhwible@mkg.com | lld:pubmed |
| pubmed-article:11496095 | pubmed:publicationType | Journal Article | lld:pubmed |
